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ABSTRACT

STRESS-INDUCED ANXIETY AND FOS IMMUNOREACTIVITY IN ADULTHOOD
FOLLOWING CHRONIC JUVENILE METHLYPHENIDATE EXPOSURE

Mercedes McWaters, M.A.
Department of Psychology
Northern Illinois University, 2016
Dr. Leslie Matuszewich, Director
Methylphenidate (MPH), or Ritalin, is the most commonly prescribed psychostimulant
for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Research has established
that MPH alleviates symptoms of ADHD short-term in humans, but research on the long-term
effects after juvenile exposure has yielded mixed results. One possible long-term effect of MPH
treatment is the alteration of neural circuits, especially dopaminergic and noradrenergic circuits
projecting to the prefrontal cortex that are implicated in ADHD symptomatology and are the
targets of MPH treatment. Long-term alterations of these circuits may impact coping with stress
later life as these same circuits mediate the stress response. Specific regions that respond to
stress include the infralimbic region of the prefrontal cortex (PFC) and the paraventricular
hypothalamic nucleus (PVN) of the hypothalamus. Therefore, the goal of this study was to
investigate the effects of chronic juvenile MPH treatment on a later acute stress experience in
adulthood. A single exposure to restraint stress increased the activation of FOS (a protein
encoded by the Fos gene) immunoreactivity in the PFC and PVN, but did not alter anxiety-like
behavior, in rats chronically treated as juveniles with MPH or vehicle. Further juvenile exposure
to oral MPH did not alter the stress-induced increases in FOS in either brain region. The absence
of long-term effects of MPH may be viewed in a positive light, as MPH did not render the rats
more sensitive to stress.
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INTRODUCTION
Attention Deficit Hyperactivity Disorder
Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral disorder commonly
diagnosed in school-aged children. Diagnosis of ADHD is at an all time high with
approximately 11% of children (roughly 6.4 million) ages 4-17 diagnosed according to the
Centers for Disease Control and Prevention ([CDC], 2011). Children diagnosed with ADHD are
more likely to suffer negative social situations than healthy age-matched controls, such as
rejection by peers, low self-esteem, and adverse family relationships (Harpin, 2005; Van der
Oord et al., 2005). Further, these negative social outcomes tend to persist later in life and
deleteriously affect social interactions and educational/occupational performance, which may
have serious implications for an individual, family, and society (for review, see Harpin, 2005).
Parents report that children with ADHD have three times as many peer problems as a healthy
child and are ten times as likely to have issues that negatively affect friendships (CDC, 2011).
Due to the undesirable symptomatology and adverse social effects, it is not surprising that
many children diagnosed with ADHD are currently undergoing treatment. Current treatment
strategies include pharmacological mediation, psychotherapy, or a combination of the two
(National Institute of Mental Health, 2016). An estimated 6.1% of children (roughly 3.6 million)
ages 4-17 are currently taking pharmacological treatment for ADHD, with the most common
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treatment being a stimulant medication such as methylphenidate (Ritalin; CDC, 2011). A
plethora of research outlines the benefits of methylphenidate (MPH) in the short-term in
addressing symptoms of ADHD, addressing issues concerning both locomotor activity and
cognitive function as discussed below (Arnsten & Dudley, 2005; for reviews see Arnsten, 2006,
Spencer, Klein, & Berridge, 2012).
There are two domains of symptoms that characterize ADHD: inattention and
hyperactivity/impulsivity. These two domains lead to the characterization of three different
types of ADHD: predominantly inattentive presentation, predominantly hyperactive-impulsive
presentation, and combined presentation. An individual who presents predominantly inattentive
symptomology likely has difficulty with organization, completion of tasks, and following
instructions. An individual who presents predominantly hyperactive-impulsive symptomology is
likely restless, fidgety, and talks a lot. This individual has difficulty sitting still for any period of
time, may interrupt others, and is more prone to accidents and injuries than other children. An
individual who presents combined symptomology will have all of the above symptoms, without
the predominance of one domain of symptoms (CDC, 2011).
Many brain regions are implicated in ADHD symptomatology with the prefrontal cortex
being the focus of much research over the past few decades. The prefrontal cortex (PFC) is a
highly evolved cortical brain region, which is essential for the regulation of attention and
behavior (for review, see Arnsten, 2009; Chudasama et al., 2003). ADHD symptoms are thought
to arise following improper levels of dopamine and norepinephrine in the PFC and subsequently
through the dysregulation of its numerous projections to multiple other regions, including
sensory and motor cortices, basal ganglia, and the cerebellum (Bonelli & Cummings, 2007;
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Alexander, DeLong, & Strick, 1986). The dysfunction of these neurotransmitters within the PFC
has been highly implicated in the inattentive symptoms, whereas dysfunction between the PFC
and other regions is implicated in hyperactivity symptoms.

Figure 1. The prefrontal cortex exerts “top-down” regulation of attention and behavior (Arnsten,
Berridge, & McCracken, 2009).
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Brain Development and ADHD
A key consideration to understanding ADHD and the effects of stimulant treatment is that
children are still developing when ADHD is diagnosed. According to the CDC (2011), the
average age of diagnosis is seven, with more severe cases being diagnosed around age five. It is
estimated that a child at age 5 will continue to develop more than 10% of his/her brain volume
through late adolescence (Reiss et al., 1996). One brain region that expands rapidly between the
ages of 5 and 11 is the prefrontal cortex; it expands by approximately one millimeter per year
(Sowell et al., 2004). This drastic increase is one reason that many researchers purport the
prefrontal cortex as a critical brain region during development and may play a crucial role in the
etiology and treatment of ADHD. The continued cortical growth and remodeling during
development may render the brain more or less sensitive to treatment, which may result in longterm effects on brain circuitry and function.
Research on the long-term effects of methylphenidate in humans on ADHD symptoms
has yielded inconclusive results, but there is evidence that methylphenidate may improve
neurocognitive function. Huang, Wang, & Chen (2012) measured the long-term effects of MPH
on symptom improvement. Drug-naïve children diagnosed with ADHD aged six through sixteen
were assessed using the test of variable of attention (TOVA) and then received 0.3-1.0 mg/kg
oral MPH two or three times daily, depending on symptom severity, over the course of a year.
Children were reassessed with the TOVA six months and one year into treatment following a
week-long MPH washout period prior to each assessment. Children who received MPH
treatment showed improvement on the TOVA measure compared to their control counterparts.
To measure the long-term neurocognitive effects of MPH, drug-naïve children diagnosed with
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ADHD aged six through twelve were assessed on the Wechsler Intelligence Scale (WISC-III)
and then received 0.3-7.0 mg/kg MPH or no treatment over the course of a year. Children were
reassessed on the WISC-III six months and one year into treatment and were off of medication at
least one week prior to assessment. Children who received MPH treatment showed
neurocognitive improvement compared to their control counterparts (Tsai et al., 2013). These
studies demonstrate the beneficial effects of one year of stimulant treatment in a critical domain
for school-aged children, learning and memory; however, the human research has not provided
much insight into other constructs that may be affected by the drug, such as stress and anxiety.
Perhaps due to the continued development of regions such as the PFC, the juvenile brain
also is more plastic than the adult brain (Urban, Waterhouse, & Gao, 2012; Urban, Li, & Gao,
2013). The PFC is a highly malleable brain region, which allows for its unique functionality
(i.e.- working memory and decision-making) and can be investigated in a variety of ways. In
rodents, whole-cell patch clamp recording was used to examine PFC cell excitability and
synaptic transmission. Urban, Waterhouse, and Gao (2012) demonstrated that the response of
the PFC to stimulants during the juvenile stage (postnatal day [PD] 15-20) in rats differs when
compared to the PFC in late adolescence and adulthood (i.e. PD 90-100). Layer five pyramidal
neurons (primary excitatory neurons) in juvenile rats showed reduced firing and synaptic
transmission when MPH was injected at doses lower than those used clinically for ADHD. The
depressive effect of MPH in juveniles is the opposite of what has been observed in adult rats and
humans, where MPH administration excited PFC neurons (Berridge et al., 2006; Urban et al.,
2012). The depressive effect observed in juveniles seems counterintuitive and contradicts an in
vitro slice study that reported excitation of layer 5-6 pyramidal neurons in young rats when MPH
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was added to a slice preparation (Andrews & Lavin, 2006). However, the methods differ
between the two approaches and the findings support that the juvenile brain responds differently
to MPH compared to the adult brain.
The highly plastic and malleable brains of children and adolescents allow for substantial
growth and development through glutamate receptor mediated plasticity. Interestingly, early
plasticity in the prefrontal cortex may be due to its unique ratio of N-methyl-D-aspartate
receptors (NMDARs; Wang, Stradtman III, Wang, & Gao, 2008). During development in most
brain regions, the NR2B subunit of the NMDAR is replaced by the NR2A subunit. However, in
the PFC, the ratio of the NR2B to the NR2A subunits stays high in normally developing
individuals, keeping it in a more “juvenile state” compared to the development of other brain
regions, which could prolong the unique plasticity of the region. Pharmacological agents, such
as methylphenidate, have been shown to affect the ratio of the NMDAR subunits. Increased
dopamine activates D2-receptors; D2 receptors alter NMDA receptor subunits (for review, see Li
& Gao, 2011). Using western blotting, Urban and colleagues (2013) found that a single dose of
MPH resulted in a significant decrease of the NR2B protein both at the surface and
intracellularly, as compared to the saline control. A comparable stimulant treatment regimen
also decreased NMDAR-mediated excitatory postsynaptic currents in the PFC in response to
stimulation (Urban, Li, & Gao, 2013). These changes suggest that methylphenidate may have
the capabilities to prolong the maturation of cortical regions and thus, preserve plasticity or at
least alter synaptic function.
To investigate brain development in children, researchers have used magnetic resonance
imaging (MRI) to examine changes in brain structures. The prefrontal cortex, basal ganglia,
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corpus callosum, and cerebellum have been characterized in terms of the total brain volume, as
well as more specific measures of gray and white matter. One concern with these studies is their
small sample sizes and lack of true control methodologies (i.e.- random assignment between
groups; Schweren, deZeeuw, & Durston, 2013), but this research is currently one of the best
options for understanding ADHD.
Using MRI measures of total brain volume, researchers can explore the neuroanatomical
correlates of ADHD. The brains of children diagnosed with ADHD are generally smaller than
healthy controls when measured during childhood and adolescence (height, weight, and
medication status were non-significant covariates; Castellanos et al., 2002). This directionality is
fairly consistent as Krain and Castellanos’ (2006) meta-analysis of published volumetric studies
yielded a significant effect of ADHD on total brain volume. Durston et al., (2004) assessed brain
volumes of 152 children/adolescents diagnosed with ADHD and 139 undiagnosed controls.
ADHD diagnosed children had approximately 3.2% smaller cerebral volumes than their age and
sex-matched counterparts; this included the frontal, parietal, temporal, and occipital lobes. More
specific morphological examination of the frontal cortex revealed that ADHD diagnosed children
had various cortical regions (e.g. lateral anterior temporal and dorsolateral) that were reduced up
to 4 mm bilaterally compared to their control counterparts (Sowell et al., 2003). Overall, the
evidence suggests that children with ADHD have decreased global brain volume, which is also
reflected in decreased volume of several frontal cortex regions.
During childhood, normally developing children experience a drastic increase in white
matter volume (Sowell, Trauner, Gamst, & Jernigan, 2002). The increase of white matter
indicates an increase in myelination, or connectivity, between cortical regions. This increase
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occurs during childhood throughout most of the brain with greater elevations specifically in the
frontal and parietal lobes (Sowell, Trauner, Gamst, & Jernigan, 2002). Importantly, the
prefrontal cortex’s increase in white matter has been linked to enhancement of tasks related to
attention and other cognitive abilities (Casey et al., 1997). Children with ADHD have been
shown to have a decrease in overall white matter volume as compared to healthy control children
(Castellanos et al., 2002), which may explain some of the cognitive symptomatology associated
with ADHD. Further, children diagnosed with ADHD have lower generalized fractional
anisotropy values (a measure of the microstructure of white matter that incorporates the packing
density, diameter, coherence of directionality, and myelination) of axons in frontostriatal tracts,
including tracts from the caudate to the dorsolateral PFC, ventrolateral PFC, and orbitofrontal
cortex; superior longitudinal fasciculus; and cingulum bundle. The superior longitudinal
fasciculus is also associated with inattention symptoms of ADHD (Chiang, Chen, Lo, Tseng, &
Gau, 2015). Thus, brain regions associated with behavioral symptoms of ADHD show decreases
in white matter volume through a number of methods.
Typically developing children also experience changes in gray matter volume. Overall,
gray matter decreases in a non-linear fashion as a result of selective pruning of connections
within the brain (Reiss et al., 1996). However, from early to late childhood (ages 6-9), humans
experience approximately a 13% increase in gray matter before experiencing the gray matter
decreases throughout late childhood, adolescence, and even adulthood (Courchesne et al., 2000).
These gray matter fluctuations occur in frontal, parietal, and occipital lobes (Sowell et al., 2004),
consistent with developing white matter regions and regions associated with ADHD
symptomology. Children with ADHD have been shown to have significant reductions in gray
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matter in the frontal lobe (superior frontal gyrus, posterior cingulated gyrus) and basal ganglia
(globus pallidus and putamen). Overmeyer et al. (2001) suggest that these findings support the
hypothesis that the dysfunction of the cortical gray matter is associated with the cognitive
network for attention and is critical for ADHD symptomatology.
In summary, the neuroanatomical evidence for ADHD has been well documented, but the
research on the effects of psychostimulants on changes in brain matter has posed some
interesting questions. There is mixed evidence that stimulant treatment has normalizing effects
on the abnormal brain structure associated with ADHD. Additionally, there is no research that
documents these types of effects on normally developing children who may take psychostimulant
treatment. Potential answers to these questions will be reviewed after discussing the common
psychostimulant treatment for ADHD, methylphenidate.

Methylphenidate
Methylphenidate is the most commonly prescribed psychostimulant for the treatment of
ADHD (Zito et al., 2000). It is classified as a psychostimulant because its mechanism of action
and structure are very similar to those of other stimulants, such as amphetamine and cocaine. In
humans and rats, MPH has a binding affinity for both DA and norepinephrine (NE) transporters,
although it has greater affinity for the DA transporter (Kuczenski & Segal, 1997). These
catecholamine transporters normally remove DA and NE from the extracellular space by
uptaking it back into the presynaptic cell. ADHD diagnosed individuals have increased levels of
DA and NE transporters, which correlate with ADHD symptomatology (Dougherty et al., 1999;
Dresel et al., 2000). MPH binds to and blocks these transporters, resulting in less DA and NE
reuptake into the presynaptic cell and greater levels of extracellular DA and NE in the synapse
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(Harvey, Sen, Deaciuc, Dwoskin, & Kantak, 2011; Kuczenski & Segal, 1997; Volkow et al.,
2001; Volkow, Fowler, Wang, Ding, & Gatley, 2002). The increases in extracellular DA and NE
can affect other postsynaptic membranes/cells by binding to the appropriate receptors and
influencing down stream mechanisms, including gene expression (Zhang et al., 2012). In the
PFC of ADHD patients, MPH is thought to stabilize extracellular DA and NE levels in order to
facilitate normal gene expression, which then normalizes behavior.
MPH affects catecholamine reuptake sites throughout the brain. The medial PFC
(mPFC) has a high concentration of norepinephrine transporters (NET) and a low concentration
of dopamine transporters (DAT) whereas the striatum has a high concentration of DAT and a
low concentration of NET (for review, see Madras, Miller, & Fischman, 2005). Research with
other psychostimulants, like cocaine, has found that DA has a higher affinity for NET in the
PFC, whereas DA uptake in the caudate and nucleus accumbens relies on DAT (Moron,
Brockington, Wise, Rocha, & Hope, 2002). Higher DAT availability in the striatum and by
extension lower extracellular dopamine levels, have been positively correlated with symptoms of
inattention in humans (Cheon et al., 2003; Dougherty et al., 1999; Tomasi et al., 2009).
However, other research has suggested that inattentive symptoms do not correlate with high
levels of DAT, but may actually be related to low levels of DAT (Volkow et al., 2007). In one
study, individuals diagnosed with ADHD who have never been medicated had lower DAT
availability and lower D2/D3 receptor availability in the caudate, nucleus accumbens, and
hypothalamus as compared to non-diagnosed individuals (Volkow et al., 2009). While a DA
deficiency hypothesis for the pathology of ADHD generally remains accepted, the causal role of
DAT availability is being challenged. There is clear evidence that low DA levels in the PFC
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correlate with symptoms of ADHD, but it is not well accepted that these low DA levels stem
directly from abnormally high DAT availability. A potential explanation for the opposing
directionality seen in the research is that DAT is up-regulated or down-regulated due to some
other dysfunction that alters DA levels (Volkow et al., 2007).
Experiments in rodents have also investigated the effects of repeated MPH treatment on
transporters. Specific animal strains have been used for studying ADHD, such as the
spontaneously hypertensive rat (SHR). The SHR strain was bred from Wistar Kyoto rats (WKY)
with high blood pressure and is a commonly used rat model for ADHD due to its hyperactive
behavior (McCarty & Kopin, 1979). Somkuwar, Darna, Kantak, & Dwoskin (2013) analyzed the
long-term effects of daily 1.5 mg/kg oral MPH from PD 28-55 on DAT function in WKY and
SHR rats as adults. DAT function was decreased in the orbitofrontal cortex of WKY, which
serves as the control strain, but no effects were observed in the striatum or in SHRs. This
suggests that MPH could have differential effects on ‘normal’ brains as compared to brains with
ADHD pathology. SHRs had a significant increase in DAT function in adulthood (PD 77-84) in
the mPFC following adolescent MPH treatment compared to SHR vehicle controls and MPH
treated WKYs. Harvey, Sen, Deaciuc, Dwoskin, & Kantak (2011) found similar results such that
1.5 mg/kg oral MPH from PD 28-55 increased DAT function in the PFC of WKYs and
decreased DAT function of SHRs and DAT function was not altered in the striatum. Together,
this research outlines that MPH during development may have long-term effects on cell function
in specific brain regions; these alterations may be dependent on the organism’s genotype.
The cortical developmental window associated with youth suggests that the PFC may be
particularly sensitive to environmental and pharmacological manipulations during childhood and
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adolescence (Arnsten, 2007; Kolb et al., 2012). As mentioned above, the frontal cortex is
smaller in children diagnosed with ADHD (and are unmedicated) compared to normally
developing children (Durston et al., 2004). Chronic methylphenidate treatment during childhood
has been shown to normalize gray matter and white matter volume reductions in the prefrontal
cortex and cerebellum of children with ADHD (for review, see Schweren, deZeeuw, & Durston,
2013). A meta-analysis established that ADHD diagnosed children have smaller brain volumes,
which can be mediated by MPH (Nakao, Radua, Rubia, & Mataix-Cois, 2011).
Much of the brain imaging research occurs only at one time point in development and
compares between diagnosis groups (e.g. ADHD v. Controls) rather than changes over time.
While the data is useful, it limits our understanding of the role of development in the volumetric
measures of brain matter. Shaw et al. (2009) investigated the effects of MPH on cortical
thickness across a four-year time period. Participants included 43 children with an average age
of 12.5 years old during the first scan and 16.4 years old during the second scan. Three groups
were assessed: normally developing/undiagnosed children, children diagnosed with ADHD who
were unmedicated, and children diagnosed with ADHD who were medicated with
psychostimulants. During the first scan/baseline, there were no significant group differences in
cortical thickness. At the time of the second scan, untreated adolescents (off medication)
diagnosed with ADHD had decreased cortical thickness (frontal gyrus, parieto-occipital region,
precentral gyrus) compared to typically developing peers and peers with ADHD who were taking
psychostimulants. This study suggests that MPH may decrease the rate of cortical thinning in
select regions, which could have implications for long-term effects on circuitry and subsequent
behavior.
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During development, administration of MPH may trigger the alteration of
monoaminergic neurons and communication, which, in turn, may cause or may result in longterm cytoarchitectual changes. These changes may normalize neural circuits of individuals with
pathologies (Shaw et al., 2009), however the mechanisms underlying the neural alterations are
not well understood. One possible neural target of MPH is third messenger systems, such as
immediate early genes, that respond to psychostimulants and can influence production of many
proteins and thus potential long-term changes for cellular phenotypes (for review, see Kovacs,
1998).

Immediate Early Genes and MPH
Previous research has shown that chronic MPH administration alters levels of FBJ
osteosarcoma oncogene (FOS) protein using immunohistochemistry. Fos is the most frequently
activated immediate early gene in the central nervous system that rapidly and transiently
responds to stimuli (Hoffman, Smith, & Verbalis, 1993). FOS, which is encoded by Fos,
controls target gene expression in the nucleus of postsynaptic cells that is involved in cellular
activation (Armstrong & Montminy, 1993). Thus, FOS acts as a third messenger that responds
to stimuli in the short-term and can affect potential long-term cell processes. A single
subcutaneous injection of 2.0 or 10.0 mg/kg MPH (PD 38) elevated FOS activity in the mPFC,
amygdala, caudate, and nucleus accumbens of juvenile male Sprague-Dawley rats (Chase,
Carrey, Brown, & Wilkinson, 2005). Acute 5.0, 10.0, and 40.0 mg/kg MPH i.p. injection in
adolescent rats (PD 35) and mice (PD 39) produced a dose-dependent increase in FOS compared
to saline treated controls (Brandon & Steiner, 2003; Hawken, Brown, Carrey, & Wilkinson,
2004).
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While prior research has demonstrated an increase in FOS after an acute injection with
MPH, research on FOS activation following chronic MPH treatment has been more challenging
to interpret. Due to the large numbers of dopamine transporters in the striatum, several studies
have focused on FOS activation in the striatum. Chase, Carrey, Brown, and Wilkinson (2005-B)
found an increase in the acute effects of MPH on FOS on juvenile rats at age PD 38 similar to the
acute effect also observed in adult rats at PD 66. However, rats subcutaneously injected with 2.0
or 10.0 mg/kg MPH from PD 25-38 had lower striatal FOS activation compared to salineinjected control rats and rats who received a single MPH dose when sacrificed two hours after
the last injection, suggesting a tolerance or desensitization following chronic treatment.
Moreover, a subset of rats was given a 4-week drug-free period after the initial treatment from
PD 25-38 and then received an acute injection of 2.0 or 10.0 mg/kg MPH on PD 66. The downregulation of FOS persisted in rats receiving the 10.0 mg/kg challenge compared to saline treated
rats after the drug-free period, but not in those receiving the 2.0 mg/kg dose. Older rats receiving
chronic MPH from PD 54-66 only exhibited an attenuated FOS response to the higher dose of
10.0 mg/kg MPH compared to saline-treated rats, but not at the 2.0 mg/kg dose. Hawken,
Brown, Carrey, and Wilkinson (2004) also found that 5.0 or 40.0 mg/kg MPH increased FOS in
the striatum in a dose dependent manner, but chronic administration of both doses attenuated
FOS expression when challenged with an acute dose of MPH. In the striatum, which has large
quantities of DAT, repeated exposure to MPH appears to reduce FOS activation tested after the
last injection and also after a withdrawal period with an acute challenge. Further, the attenuation
of FOS activation occurs to a range of MPH doses during the juvenile stage, but only to a higher
dose during adulthood.
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Chronic MPH has been shown to increase FOS activity in other brain regions that are
thought to play a critical role in ADHD. Chronic 2.0 and 10.0 mg/kg subcutaneous
methylphenidate exposure from PD 25-38 has been shown to increase FOS in the nucleus
accumbens (Chase, Carrey, Brown, & Wilkinson, 2005) and prefrontal cortex (Koda et al., 2010)
on PD 38, 2 hours following the last injection. Likewise, 2.0 mg/kg MPH (i.p) injected from PD
20-34 increased Fos mRNA expression compared to saline in the ventral tegmental area of mice
24 hours after the last injection (Alcantara, Warren, Parise, Iniguez, & Bolanos-Guzman, 2014).
This increase in gene expression also persisted in a subset of animals that were sacrificed for
analysis two months after the last MPH injection. Despite the focus on the PFC for
understanding ADHD and the effects of MPH, little additional basic research has investigated the
effect of MPH on IEGs in the PFC and potential subsequent long-term alterations of messenger
systems.

Long-Term Effects of MPH on Behavior
The long-term effects of MPH on brain catecholamine systems and immediate early gene
expression may be critical to long-term behavioral changes following repeated psychostimulant
exposure. Many behaviors have been studied following chronic MPH exposure during juvenile
periods, including anxiety, depression, addiction liability, learning, and memory (Dow-Edwards,
Weedon, & Hellman, 2008; Galizio, McKinney, Cerutti, & Pitts, 2009, Gray et al., 2007; Zhu,
Weedon, & Dow-Edwards, 2007). Research has explored whether or not developmental MPH
administration also influences behavior in adulthood, after MPH treatment has been
discontinued. While the immediate effects during MPH treatment are well known in humans, it
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is difficult to infer what behavioral effects may persist indefinitely following treatment and what
mechanism(s) is(are) responsible for a long-lasting behavior (Andersen, 2005).
One behavior that has been studied following MPH treatment is anxiety. MPH influences
neural function at several brain regions associated with anxiety, including the prefrontal cortex
(for review, see Davidson, 2002). Moreover, MPH targets norepinephrine and dopamine
systems, which may modulate anxiety and contribute to the anxiolytic effects of MPH (Snircova
et al., 2015). Despite the logical connection, research in humans and rodents shows conflicting
results, with some studies suggesting that MPH decreases anxiety and other studies suggesting
increases in anxiety following methylphenidate treatment. In children diagnosed with ADHD
and social phobia, low doses of MPH (0.5-1.0 mg/kg) reduced anxiety scores (Golubchik, Sever,
and Weizman, 2014). Children diagnosed with ADHD and comorbid social phobia were
assessed on the Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-CA).
Children meeting the LSAS-CA criterion of social anxiety began a 0.5-1.0 mg/kg dose of MPH,
which continued for twelve weeks. The children given MPH exhibited significantly reduced
anxiety scores, suggesting that MPH decreases the severity of social phobia in children also
diagnosed with ADHD. In a separate study, patients taking 5.0 mg/kg methylphenidate (with the
dose being increased by 5.0 mg/kg a week up to 40.0 mg/kg) had significant reductions of
anxiety symptoms when measured on the Conner’s Parent Rating Scale (CPRS) every two weeks
during eight weeks of treatment (Snircova et al., 2015). There is a potential confound of
comorbid ADHD and anxiety diagnosis; research suggests that preexisting levels of anxiety alter
the response to methylphenidate, measured with the CPRS and Conner’s Teacher Rating Scale,
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such that children with higher anxiety levels have a lower response to methylphenidate (Moshe,
Karni, & Tirosh, 2012).
In rodents, anxiety-like behaviors can be measured using the elevated plus maze (EPM;
Walf & Frye, 2007). The EPM apparatus consists of four arms, two of which are enclosed and
two of which are open. These arms are connected to form a plus shape that sits above ground
level. Anxiety-like behavior is measured in this apparatus based upon the amount of time a
rodent spends in the open arms versus the closed arms. A rodent that spends more time in the
open arms is thought to be less anxious than a rat that spends more time in the closed arms.
Although there are other behavioral tests that measure anxiety-like behavior in rodents, the EPM
is one of the most commonly used (Walf & Frye, 2007).
Following chronic MPH exposure, the research findings have reported increases,
decreases, and no change in anxiety-like behaviors (Bolanos et al., 2003; McFadyen-Leussis et
al., 2004; Gray et al., 2007; Brookshire & Jones, 2012). For example, Bolanos, Barrot, Berton,
Wallace-Black, and Nestler (2003) assessed rats in adulthood six weeks after chronic
administration of 2.0 mg/kg i.p. MPH twice daily from PD 20-35. MPH treated rats spent
significantly less time in the open arms of the EPM than their control counterparts in adulthood.
However, other researchers have found that MPH decreases or has no effect on anxiety-like
behaviors in rodents. Carrey, McFadyen, and Brown (2000) subcutaneously injected mice with a
high dose of 40.0 mg/kg MPH or saline from PD 26-32 and then tested the mice on PD33
immediately following MPH. As compared to the saline pretreated mice, MPH pretreated mice
spent significantly more time in the open arms of the EPM on PD 33, one day following the last
injection. Mice that received MPH on PD 33 had significantly more entries into the open arms
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than the saline treated mice, but there was no significant difference in duration spent in the open
arms indicating an increase in locomotion, but not necessarily a reduction in anxiety. It has also
been shown that no dose of methylphenidate (2.5, 5.0, 10.0, 20.0, 40.0, or 80.0 mg/kg) in mice
from PD 26-32 affects open field exploration or elevated plus maze measures of anxiety
(McFadyen, Brown, & Carrey, 2002). Research on the effects of MPH treatment on anxiety-like
behavior in rodents has yielded mixed results, but time period and duration of treatment likely
play a role in long-term behavioral changes.
The long-term effects of in utero exposure to MPH also have been investigated on
anxiety-related behaviors. MPH was administered to dams to expose pups in utero during
embryonic (E) days 8-10, 12-14, and 16-18, which correspond to the time when catecholamine
levels are detected during embryonic development in rodents (McFadyen-Leuissis, Lewis, Bond,
Carrey, & Brown, 2004; Voorn, Kalsbeek, Jorritsma-Byham, & Groenewegen, 1988). Notably,
DA is first detected around E 10 and NE is first detected at approximately E 12 (for review, see
Berger-Sweeney & Hohmann, 1997; Voorn, Kalsbeek, Jorritsma-Byham, & Groenewegen,
1988). All mice were then tested in the EPM at PD 60. Mice exposed to MPH on E 8-10
displayed a decrease in anxiety-related behaviors compared to their saline-treated counterparts,
however no other group differed from controls on any EPM measures; the difference observed in
this developmental window suggests that dopamine may be important in the long-term effects of
early MPH administration. As rats are born immature compared to humans, PD 7 in rats is
developmentally equivalent to the end of the third trimester/birth in humans (Dobbing & Sands,
1979). Rats administered 5.0 mg/kg i.p. MPH twice daily from PD 7-35 showed a decrease in
anxiety when tested on PD 134. Rats that received MPH spent significantly more time in the
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open arms than saline treated rats, suggesting decreased anxiety (Gray et al., 2007).
Collectively, the research suggests that MPH, when administered during early developmental
periods, can have long-term effects on anxiety-like behaviors.
Other behavioral tests of anxiety have also yielded mixed results in regards to the delayed
behavioral effects following early MPH exposure. Daily treatment (PD 11-20) of rat pups with
2.0 or 5.0 mg/kg i.p. MPH had effects on several measures of anxiety in adulthood (Crawford et
al., 2013). On PD 60, rats were tested on a conditioned place preference task to assess novel
exploration of light (typically aversive) and dark environments (typically attractive). This task is
similar to the light-dark box exploration task, which measures anxiety-like behaviors by
preference of dark areas and avoidance of light areas (Bourin & Hascoet, 2003). Rats injected
with 5.0 mg/kg MPH per day from PD 11-20 spent significantly more time in the white
compartment than saline treated rats, suggesting that the light environment was less anxietyprovoking. However, when tested in the EPM, rats treated with 5.0 mg/kg MPH spent less time
in the open arms than rats treated with saline or rats treated with 2.0 mg/kg MPH, suggesting an
increase in anxiety with the higher dose. Together, these data suggest that MPH has effects on
anxiety-like behaviors, but time and duration of treatment may influence the directionality of the
relationship.
Although there is no clear directionality from other studies on the long-term effects of
MPH on anxiety-like behaviors in rodents, there is still evidence that MPH during development
has lasting neuropharmacological effects, particularly in the PFC. Moreover, due to the PFC’s
involvement in numerous functions, there is potential for the long-term effects of MPH to
influence many behavioral and physiological processes. During development, between one year
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old and five years old in humans, there is a vast overproduction of synapses in the PFC, followed
by an overproduction of spines (Petanjek et al., 2011). During maturation, the PFC
eliminates/prunes excess synapses at the slowest rate compared to other regions (Elston, Oga, &
Fujita, 2009), which is thought to give rise to the PFC’s high potential for alteration by
environmental or pharmacological influences. In rodents, the same general events occur in the
PFC, but at a slightly different timeline seeing as humans are more precocious at birth (see figure
2 by Kolb et al., 2012). The shorter lifespan of the rat also dictates that the rat brain has to
develop much faster than the human brain, with peak synapse density being achieved by
postnatal day 30 (Nakamura, Kobayashi, Ohashi, & Ando, 1999). Thus, given the later
developmental window of the PFC and the evidence that MPH can affect cortical function in the
short and long-term, MPH treatment during postnatal development in the rat could alter PFC
circuits and subsequent PFC-mediated behaviors, including those in response to stress.

Figure 2. Time line of brain development in humans and rodents (Kolb et al., 2012).
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Stress
Much of the same circuitry that is targeted by methylphenidate treatment is also activated
in response to stress. Exposure to MPH during the juvenile period, when synaptogenesis and
cytoarchitectual changes occur, might render the rats more or less vulnerable to stress and more
or less prone to exhibit anxiety-like behaviors later in adulthood (for review see Andersen,
2003). The juvenile exposure to MPH may alter neural circuits that respond to and coordinate
the stress response, including the prefrontal cortex and hypothalamus.
The construct of stress can be viewed as the psychological and physiological response to
stimuli from the environment that disrupts homeostasis and is necessary for life (Dallman, 2003).
Humans and animals experience a variety of stressors, including those of a physical or
psychosocial nature. Physical stressors would include stressors that predominantly affect the
animal physically, such as immunological challenges and pharmacological stressors, whereas
psychosocial stressors would include stressors that do not require physicality, such as isolation or
wet bedding (Segerstrom & Miller, 2004). Restraint or immobilization stress is often used to
elicit the stress response due to its unique ability to act as a physical and psychological stressor;
it elicits most allostatic responses and the animal has the perceived inability to escape (Glavin et
al., 1994; McLaughlin, Gomez, Baran, & Conrad, 2007). In addition to considering the type of
stressor, the intensity and duration of the stressor have implications for the magnitude of the
stress response (Chowdhury, Fujioka, & Nakamura, 2000; Reyes, Walker, DeCino, Hogenesch,
& Sawchenko, 2003). In general, many types stressors will physiologically affect the organism
by activating the following stress systems.
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Hypothalamic Pituitary Adrenal Axis
The body’s major neuroendocrine response to stress is activation of the hypothalamicpituitary-adrenal (HPA) axis (Cullinan et al., 1995). In mammals, the activation of the HPA axis
is often viewed as a stress response and a subsequent compensatory mechanism that restores
homeostasis (McEwen, 2005). Activation of the HPA axis by a stressor stimulates the secretion
of corticotrophin-releasing factor (CRF) from the paraventricular hypothalamic nucleus (PVN).
After release from the hypothalamus, CRF travels via the circulatory system to the anterior
pituitary gland, where the presence of CRF stimulates the secretion of adrenocroticotropic
hormone (ACTH). ACTH travels then to the adrenal cortex and stimulates the secretion of
glucocorticoids (GC; i.e. cortisol in humans/corticosterone in rats). After release,
glucocorticoids travel throughout the body and into the brain, binding to glucocorticoid
receptors. In the brain, glucocorticoid receptors are found in high densities in the mPFC and
amygdala. Interestingly, the activation of glucocorticoid receptors in the amygdala results in a
feed-forward activation of the HPA axis further increasing the stress response, whereas the
activation of glucocorticoid receptors in the prefrontal cortex results in an inhibition of the HPA
axis by inhibiting CRF release (Jankord & Herman, 2008).
There is substantial evidence that acute restraint stress activates the HPA axis as
evidenced by increases in pituitary and adrenal hormones. Male and female Sprague Dawley
rats exposed to 30 minutes of restraint had significantly increased plasma ACTH and CORT
levels in tail vein blood immediately following stress (Babb, Masini, Day, & Campeau, 2013).
Male Sprague-Dawley rats show an increase in plasma corticosterone levels in trunk blood in
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response to 30 minutes acute restraint stress immediately and 30 minutes after the end of stress
(Mantsch et al. 2007; Bauer, Perks, Lightman, & Shanks, 2001).
The PVN of the hypothalamus is believed to mediate the stress response. The PVN is
innervated by many brain regions including brain stem neurons (sensory information from the
nucleus of the solitary tract), hypothalamus (GABA agonists in hypothalamus decrease
circulating glucocorticoid levels following stress), medial prefrontal cortex (inhibitory effect on
HPA axis activity), and medial and central nuclei of the amygdala (excitatory effect on HPA axis
activity; for review, see Smith & Vale, 2006). In turn, the PVN projects to many regions,
including the ventral tegmental area, periaqueductal gray, reticular formation, dorsal raphe, and
locus coeruleus (Geerling, Shin, Chimenti, & Loewy, 2010). This vast network of inputs and
outputs makes the PVN uniquely able to orchestrate a response to a stressor. To test whether the
PVN is critical for the physiological and hormonal activation associated with acute stress, the
PVN of male Wistar rats was bilaterally injected with a nonspecific synaptic blocker (cobalt
chloride), which blocks the neuroendocrine and autonomic responses associated with acute stress
(Busnardo, Tavares, Resstel, Elias, & Correa, 2010). Rats that received the blocker in the PVN
had decreased mean arterial pressure, plasma corticosterone, heart rate, and tail temperature
throughout the 60 minute restraint as compared to control stressed rats. The PVN is likely a key
region that mediates the response to stress.

Sympathetic Nervous System/Sympathoadrenomedullary System
Acute and chronic stress are known to activate multiple peripheral and central branches
of the sympathetic nervous system (SNS), alongside the HPA axis. Activation of the sympathetic
branch of the autonomic nervous system is one of the fastest responses to stress. One of its key
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characteristics is the secretion of norepinephrine from the adrenal medulla and locus coeruleus
(LC) located in the pons (for review, see Tsigos & Chrousos, 2002). Elevated norepinephrine
levels are responsible for the “fight or flight” reaction to stress and thus, contribute to physical
arousal including increased heart rate, appropriate allocation of blood flow, and glucose
metabolism for energy. Male Wistar rats placed in acute restraint stress show increased heart
rate during 60 minutes of restraint as compared to baseline rates (Crestani et al., 2009). This
stress-induced enhanced state of arousal mediated by norepinephrine and the LC is thought to
serve as an adaptation to help respond to the threat and then re-establish homeostasis (for review,
see Chrousos, 2009). Further, the LC/norepinephrine system is closely intertwined with the HPA
axis, as the LC receives many CRF afferents and is directly influenced by CRF (Jedema &
Grace, 2004), including projections from central nuclei of the amygdala (Van Bockstaele, Bajic,
Proudfit, & Valentino, 2001) and the PVN (Reyes, Valentino, Xu, & Van Bockstaele, 2005;
Valentino, Page, Van Bockstaele, & Aston-Jones, 1992). Together, the HPA axis and
sympathoadrenomedullary system orchestrate the physiological response to stress, which occurs
to help restore homeostasis.

Monoaminergic Systems
Acute stress has been shown to alter catecholamine levels within multiple brain regions
separate from the SNS (Abercrombie, Keefe, DiFrischia, & Zigmond, 1989; Cabib & PuglisiAllegra, 2012; Flugge, van Kampen, & Janneke Mijnster, 2004; Pascucci et al., 2007; Valenti,
Gill, and Grace, 2012). Generally, acute restraint stress robustly increases DA in
mesocorticolimbic pathways, which originates in the VTA and projects to the PFC and nucleus
accumbens; this pathway is implicated in emotion and cognitive function, including attention
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(for review, see Piazza & Le Moal, 1998). Catecholamine increases in the PFC are involved in
the selective attention to important stimuli (Rossi, Pessoa, Desimone, & Ungerleider, 2009).
Abercrombie, Keefe, DiFrischia, & Zigmond (1989) found significant increases in DA in the
medial prefrontal cortex, striatum, and nucleus accumbens during intermittent tail shock stress.
Intracerebral microdialysis revealed that NE levels in the PFC significantly increase during and
after immobilization stress (Nakane, Shimizu, & Hori, 1994). Single unit extracellular
recordings in the VTA show that dopaminergic neuronal firing increases following two hours of
restraint stress (Valenti, Gill, & Grace, 2012). Utilizing microdialysis to measure NE and DA
during a novel 3 hour restraint stressor, Pascucci and colleagues (2007) found that adult male rats
had a short-lived increase of NE (from approximately 20 minutes to 80 minutes into the stressor)
and a short (at 20 minutes) and a longer-lasting increase of DA (from approximately 80 minutes
until the end of restraint, when collection ceased) in the mPFC. Overall, the research purports
that catecholamines are released in response to stress, specifically in the PFC.

Acute Restraint Stress and Anxiety
Stress-induced activation of monoaminergic neurons in concert with the HPA axis and
SNS systems results in a variety of behavioral and physiological responses. Acute stress elicits
behavioral changes in rodents indicative of anxiety and depression. Acute restraint stress has
been shown to increase anxiety-like behaviors in the elevated plus maze. Rats restrained for one
hour spent significantly less time in open arms and had fewer arm entries than unrestrained
controls 24 hours after the end of stress (Reis et al., 2011). In addition, two hours of supine
restraint stress reduced overall open field exploration (Zafar, Pare, & Tejani-Butt, 1997) and
increased immobility/depression in a forced swim test (Sevgi, Ozek, & Eroglu, 2006). The
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effects of stress in rodents parallel the human literature, which supports the role of stress in
contributing to anxiety and affective disorders (Myers-Schulz & Koenigs, 2012).

Stress and FOS
As discussed previously, FOS has been shown to be expressed in response to cellular
activation. FOS is increased following methylphenidate treatment, catecholamine activation, and
in response to stress. Given the large number of brain regions that become activated in response
to stress, FOS provides an excellent description of that activation (Chowdhury, Fujioka, &
Nakamura, 2000; Cullinan, Herman, Battaglia, Akil, & Watson, 1995; Imaki et al., 1995; Zavala,
Fernandez, & Gosselink, 2011). Chowdhury, Fujioka, & Nakamura (2000) exposed male
Sprague-Dawley rats to varying time periods of restraint stress (0.5, 1, 2, and 4 hours) and found
a significant increase in number of FOS positive cells immediately following stress in the PVN
and LC for all durations of stress compared to non-stressed controls. An increase in Fos mRNA
expression has also been observed 30 minutes after 30 minutes of restraint stress in an array of
brain regions, including: orbital cortex, infralimbic and cingulate regions of the PFC, CA1 of
hippocampus, medial amygdala, and hypothalamic paraventricular nuclei (Cullinan, Herman,
Battaglia, Akil, & Watson, 1995). Male and female Sprague-Dawley rats also exhibit increased
FOS and glucocorticoid receptor co-expression in PVN neurons 2 hours following 30 minutes of
acute restraint stress (Zavala, Fernandez, & Gosselink, 2011). Acute restraint stress is a reliable
method of quickly activating multiple stress systems within the brain and body.
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Rationale and Hypotheses
The current experiment assessed the long-term effects of MPH exposure during a critical
period of early brain development (periadolescence). We hypothesized that MPH exposure
during critical periods of development may affect neural circuits, such that a stressor affecting
the same circuits in adulthood yields a reduced stress response when compared to animals not
previously exposed to MPH. We assessed whether juvenile MPH treatment altered a later stress
response via adult FOS activation in the PVN and PFC, which are neural regions that stress is
known to activate in response to acute restraint stress. Further, we explored whether juvenile
exposure to MPH alters adult anxiety-like behaviors generally or following acute restraint stress,
as measured by the EPM. Figure 3 provides a summary of the groups that were treated as
juveniles and then tested as adults.

Figure 3. Independent variables with sample sizes.

Hypotheses 1: Adult FOS Activation Following Juvenile MPH Treatment
Hypothesis 1a: We expected low constituent or basal levels of FOS activation within the PVN
and PFC; these basal levels would not differ between MPH and vehicle treated rats.
Hypothesis 1b: Following acute restraint stress, we expected FOS activation to increase for
vehicle treated animals in both brain regions, supporting previous research (Cullinan et al.,
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1995). MPH treated rats would also exhibit a stress-induced increase in FOS activation,
although we hypothesized that the increase would be attenuated.

Hypotheses 2: Adult Behaviors Following Juvenile MPH Treatment
Hypothesis 2a: We expected no main effect of drug treatment in the open field on measurements
of distance traveled and speed based on prior research (McFadyen, Brown, & Carrey, 2002;
Kuczenski & Segal, 2002).
Hypothesis 2b: Consistent with previous research, we expected that MPH treated rats in both
stress and no stress conditions would spend more time in the open arms of the elevated plus
maze than their vehicle treated counterparts (Gray et al., 2007). Further, we expected that
stressed rats in both the methylphenidate and vehicle conditions would spend less time in the
open arms (Gameiro et al., 2006).

Clinical and Translational Implications
ADHD is the most commonly diagnosed neurobehavioral disorder in children ages 4-17;
and MPH is the most commonly prescribed psychostimulant for its treatment due to its
effectiveness. Despite of MPH’s potential to alter a developmentally plastic and vulnerable
brain, little is understood about its long-term effects on stress systems. Rodent models are useful
for studying the long-term effects on a shorter time scale due to the faster development of
rodents (Andersen, 2003). Rodents have comparable stress systems to humans and therefore are
good candidates for translational research on stress within a shorter time period (Sutanto & de
Kloet, 1994).
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Much of the research on the pharmacological effects of MPH on the brain has been
conducted in rodents. In many of those published studies, rodents were administered MPH
through intraperitoneal (i.p.) injections. However, in humans, MPH is commonly administered
orally. These two routes of administration differ in regards to their pharmacodynamics, such that
oral MPH administration has a much slower effect on the brain than an intraperitoneal (i.p.)
injection due to the need to travel through the digestive tract before it can reach the bloodstream
and the brain, (see figure 4 from Kuczenski & Segal, 2005). There is also a greater increase in
prefrontal cortex levels of dopamine following MPH i.p. injections compared to oral
administration (Gerasimov et al., 2000). The slower absorption rate of MPH by the
gastrointestinal tract, as well as the heightened metabolism of MPH to ritalinic acid (which does
not provide psychostimulant effects), most likely accounts for the differences observed in the
PFC catecholamines (Gerasimov et al., 2000).

Figure 4. Theoretical plasma concentrations of methylphenidate after oral administration in
humans and intraperitoneal administration in rats (Kuczenski & Segal, 2005).
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Oral methylphenidate administration research began using intragastric/oral gavage
methods (Gerasimov et al., 2000), but oral gavage has been shown to activate the stress response
in rats as measured by plasma corticosterone levels (Brown, Dinger, & Levine, 2000). A
relatively recent method by Ferguson and Boctor (2009) has provided procedures for oral
administration of methylphenidate to rodents while bypassing the potential stress of oral gavage.
This method involves dissolving methylphenidate in water, pipetting each rat’s respective 2.0
mg/kg dose of the solution onto a vanilla wafer cookie that is proportionally 1/1000th of each
rat’s body weight, and allowing the cookie to dry before feeding. A 2.0 mg/kg dose on a cookie
yielded similar blood plasma levels as the range used for treatment of children (i.e. 8-40 ng/ml;
Swanson & Volkow, 2002). In boys aged 7-12 years old, a 0.65 mg/kg dose of methylphenidate
yields a blood plasma level of approximately 20.2 ng/ml (Shaywitz et al., 1982). In male Wistar
rats (that were fasted overnight), the 2.0 mg/kg dose resulted in plasma levels around 36 ng/ml
(Aoyama, Kotaki, & Iga, 1990). The popularity of oral administration in methylphenidate
research is growing because it better parallels human oral administration and eliminates the
unnecessary stress associated with other administration methods. This experiment administered
MPH orally in rats.
The developmental period of rodents differs in absolute ages from humans due to their
shorter life spans (Andersen, 2003). Typically, humans are diagnosed with and begin
pharmacological treatment for ADHD during childhood and early adolescence. In rats, PD 2135 translates to human childhood and is considered a juvenile/periadolescent period (see figure 5
from Andersen, 2003). During this period, rats, similar to humans, have a vast
overproduction/overshoot of synapses and receptors, which are subsequently pruned and
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eliminated (for review, see Andersen, 2003 and Kolb et al., 2012). Pruning results in
approximately a 40% reduction in frontal cortex synaptic density. Importantly, developmental
changes within regions parallel functionality (Andersen, Thompson, Rutstein, Hostetter, &
Teicher, 2000). Understanding the long-term effects of MPH may be beneficial in treating with
the drug more effectively with fewer side effects. Given the large number of children prescribed
the medication, further characterizing long-term effects are critical when considering the
immediate and long-term welfare of the patient.

Figure 5. A relative comparison of ages and stages of human versus rat development (Andersen,
2003).

METHODS
Animals and Housing
Twelve litters of male Sprague-Dawley rats were weaned from their mothers at postnatal
day (PD) 21. Sixty rats were selected from those litters and pair-housed on a 12:12h light:dark
cycle (lights on at 7:00h and off at 19:00h) in plastic cages with aspen chip bedding. All rats
received unrestricted access to food and water in a temperature-controlled room (22 ± 2 °C)
throughout the experiment. All procedures were in adherence to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals (8th edition; National Research Council,
2011) and approved by the local institutional animal care and use committee.

Juvenile Drug Exposure
Oral Methylphenidate. Two mg/kg of methylphenidate HCl (1.6 mg/kg free base; Sigma
Laboratories, St. Louis, MO, USA) dissolved in water or vehicle/water was pipetted onto a
vanilla wafer cookie (Market Pantry; Target Corporations). This oral method of drug exposure
was chosen to emulate the most common route of administration in humans (see above Clinical
and Translational Implications). Similarly, the 2.0 mg/kg dose was chosen to yield similar blood
plasma levels as the targeted range in human dosing (Aoyama, Kotaki, & Iga, 1990; Swanson &
Volkow, 2002).
Treatment of Juveniles with Methylphenidate. To habituate the rats to the cookie, rats
received a crumbled cookie in their home cage from PD 18 to PD 20 (habituation for 3 days prior
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to weaning). Following Ferguson and Boctor’s (2009) oral administration protocol, from PD 21
to PD 35 rats were weighed daily at 09:00h and cookies were cut to weigh approximately
1/1000th of the rats’ body weights. Methylphenidate dissolved in water or vehicle/water was
pipetted onto the cookie and allowed to dry for approximately 2 hours. At 11:00 h, rats were
moved into small (12 width x 18 height x 28 length cm), transparent, individual cages, where
they received and ate their cookie. After eating the cookie with the 2.0 mg/kg dose of
methylphenidate or vehicle, rats were returned to their normal, pair-housed home cages. One rat
that did not eat the cookie on PD 21 but ate on PD 22, received a cookie on PD 36 to equate the
total number of drug exposures. Two rats that did not eat their cookie on the first two days were
excluded from the experiment. Following these 15 days of drug exposure, rats were allowed to
age without further experimentation until approximately PD 90-120.

Adult Behavioral Testing and Stress Exposure
In adulthood (PD 90-120), rats’ motor behavior was assessed in open field (OF) for 30
minutes. Three days following OF, rats were quasi-randomly assigned to 1 of 4 conditions: 1)
restrained for 1 hour (a stressor known to activate the HPA axis) and tested in the elevated plus
maze (EPM; n= 16); 2) restrained for 1 hour only (n= 14); 3) tested in EPM only (n= 16); or 4)
neither stressed nor tested in EPM (n= 14). Rats were anesthetized 45 minutes after the end of
restraint, 35 minutes after the end of EPM, or 3 days after open field, depending on the
behavioral testing condition and then perfused for immunohistochemistry (IHC). Predicated on
previous literature and a power analysis, we expected that an n size of 8 would ensure adequate
power for the behavioral stress response and an n size of 4 would ensure adequate power for
analysis of FOS. For the power analysis, a statistical power of 0.8 was used to minimize the
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chance of type II error, an alpha level of 0.05 was used to reach significance, and we anticipate a
moderate to large effect size of .35.

Figure 6. Methodological timeline.
Open Field. Open field (OF) is a commonly used task to measure general motor
function. To test motor behavior, we used a large plywood box (75×75×29 cm) painted grey for
open field testing. Each rat was placed into the open field facing the back right corner and was
permitted to explore for 30 minutes. Using an overhead bullet camera, the rats’ distance traveled
was recorded by a DVD recorder. The digital recording was analyzed using Noldus Ethovision
3.0 program for the full 30 minutes and in five-minute intervals, resulting in 6 time periods
during the 30 minutes.
Elevated Plus Maze. Elevated plus maze (EPM) is a well-accepted measure of anxiety in
rats (Walf & Frye, 2007). The procedures used are similar to those used previously by our
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laboratory (Matuszewich et al., 2007). The apparatus consisted of four arms: two open arms
without walls and two enclosed arms with walls. All arms were approximately 11 cm x 50.5 cm.
These arms were attached to a central square (approximately 10 cm x 10 cm) at 90 degree angles
to form a plus sign shape. The entire apparatus was elevated approximately 48 cm above the
floor. The testing room was dark, but dimly lit with red-lighting to aid the experimenter’s vision.
Testing in the dark is thought to increase the likelihood of the rat moving onto the open arms
(Violle, Balandras, Le Roux, Desor, & Schroeder, 2009).
Five minutes prior to testing, each rat was placed into the experiment room to allow for
habituation to the red light. For testing, the rat was placed individually onto the apparatus with
their body in a closed arm facing the central square. The rat was allowed to explore the maze for
five minutes and then was returned to his home cage. Between rats, the maze was cleaned with a
disinfectant solution in order to eliminate odor cues from one subject to another. Using an
overhead bullet camera, the rats’ path was recorded with a DVD recorder. This data was handscored for open arm entries, total arm entries, and time spent in both open and closed arms. All
four paws had to be in the open or closed arm to count as an arm entry and duration within that
arm. The center region of the maze was not included in analysis unless an animal traversed the
center going from an open arm to an open arm or a close arm to a closed arm, in which the time
spent in the center counted as open or closed, respectively.
Acute Restraint Stress. Acute restraint stress has been shown to be an effective stressor
for rats; this stressor elicits activation of the HPA axis (Babb, Masini, Day, & Campeau, 2013).
For sixty minutes, each rat in the stress condition was placed in a clear Plexiglas cylinder with
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breathing holes (Harvard Apparatus, Hollison, MA) and then placed into a standard cage.
Following stress, the rats were returned to their home cage.

Immunohistochemistry
Rats were deeply anesthetized with 0.2 mL Euthasol and perfused via the left ventricle
with 0.1 M phosphate buffer and 4% paraformaldehyde. Brains were immersed in
paraformaldehyde overnight at 2°C, then transferred into fresh 30% sucrose solution daily for six
days or until saturated. Brains were serially sectioned, coronally at a thickness of 40 μm, and
sections were placed in a cryoprotectant antifreeze solution in a -20°C freezer until staining.
Standard avidin:biotinylated enzyme complex (ABC) immunohistochemistry was used
with commercially available materials to stain tissue for FOS; these protocols were adapted from
a FOS staining protocol used on prairie vole tissue (Grippo et al., 2007; Grippo et al., 2010).
Sections were incubated in PBS for 24 hours, washed with phenylhydrazine, and incubated in
rabbit polyclonal antibody for FOS protein with 0.4% Triton-X for ~42 hours at 2°C. Sections
were then incubated in biotin-goat anti-Rabbit IgG (Vector, USA) for one hour. Next, sections
were incubated in avidin-biotin peroxidase complex for one hour, washed with sodium acetate,
and incubated in Nickel-DAB solution for 15 minutes. Brain sections were then mounted on
slides, dehydrated, and coverslipped using Histomount.
We assessed the number of cells that were immunopositive for FOS in the paraventricular
hypothalamic nucleus and infralimbic prefrontal cortex by manually counting cells with stained
nuclei (FOS activated cells: cells met a pixel density threshold requirement of less than 200 to be
considered a cell) using Image J software and a standardized sampling area per region. Brain
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regions were outlined using corresponding cresyl violet stained tissue. The PFC area was
defined from 2.7- 3.7 anterior to bregma, 4.5-5.7 D/V, and 0.0-1.0 M/L (figure 7; Paxinos &
Watson, 2005). Five rectangular shaped regions of interest were placed in the infralimbic
prefrontal cortex to span the dorsal, ventral, medial, and lateral regions of the area and cells will
be assessed per area squared (the average area for the ROI sets was 293983 μm2). The PVN was
counted at the midhypothalamic level, 1.4- 1.88 mm posterior to bregma, 7.5-8.5 D/V, and 0.00.7 M/L (figure 8; Paxinos & Watson, 2005). A triangular shaped region of interest was placed
on the dorsal horn of the PVN and cells were assessed per area squared (the average area for the
ROI sets was 17777 μm2). Both regions were blindly double counted by the same rater and the
counts were averaged per region.

Figure 7. Stereotaxic image depicting the area of the infralimbic prefrontal cortex (Paxinos &
Watson, 2005).
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Figure 8. Stereotaxic image depicting the area of the dorsal horn of the paraventricular
hypothalamic nucleus (Paxinos & Watson, 2005).

Statistics
Body Weight Gain. A 2 (drug condition) x 15 (day) repeated measures ANOVA was
used to assess body weight gain during the 15 days of drug treatment. For specific body weight
comparisons on the first and final days of drug treatment, independent t-tests were conducted.
Open Field. A 1 way ANOVA was used to assess the influence of drug condition on
total distance traveled in the open field. A 2 (drug condition) x 6 (5 minute time bins) repeated
measures ANOVA was conducted for distance traveled to assess habituation to the open field.
Elevated Plus Maze A 2 (drug condition) x 2 (stress condition) ANOVA was conducted
to assess drug condition and stress condition differences in the total duration (seconds) on the
open arms and the proportion of time spent in the open arms of the maze (open arm
duration/open + closed arm duration), and number of open and total arm entries. A chi square
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test was used to assess whether there were group differences in the percentage of rats that fell
while in the elevated plus maze.
FOS Activation A 2 (drug condition) x 2 (stress condition) ANOVA was conducted to
assess drug condition and stress condition differences in the number of FOS stained cells per
area for each brain region. Graphical representations of FOS stained nuclei are percentages as
compared to the vehicle-no stress control group.
Post hoc analyses To further analyze any significant differences within the results, we
used Bonferroni post hoc analyses. We also tested for sphericity (Mauchly) on the repeated
measures analysis to ensure the variance of all of the independent variables were equal; when
sphericity was violated, we followed up with a Greenhouse Geisser correction. For the
correction, the degrees of freedom was rounded to the nearest whole number.

RESULTS
Body Weight During Treatment and Testing
On the day of weaning (PD 21), there were no significant body weight differences
between MPH (n= 30) and vehicle-assigned groups (n= 30; t(58) = 0.141, p= 0.888; figure 9).
Following two weeks of treatment (PD 35), there were still no significant body weight
differences between MPH and vehicle-assigned groups (t(58) = 0.282, p= 0.779). All rats gained
weight over the treatment period (F(2,98)= 4993.601, p< 0.001) and both treatment groups
gained weight at similar rates (F(2,98)= 0.244, p= 0.746). There were still no significant body
weight differences between MPH and vehicle-assigned groups on the day of open field testing
(t(58) = 0.132, p= 0.895) or the day of EPM/perfusions (t(58) = 0.004, p= 0.997).
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Figure 9. Body weight gain during chronic juvenile methylphenidate treatment. Values are
means ± SEM.
Locomotion
On PD 98 (on average), approximately 63 days after the last MPH treatment, rats were
placed into an open field apparatus to assess forward locomotion. There were no significant
differences between MPH (n= 30) and vehicle-treated (n= 30) groups on total distance traveled
in the open field (t(58) = -0.783, p= 0.437; figure 10). Over the 30 minutes, all rats significantly
reduced the distance traveled (F(4,208)= 338.166, p< 0.001), however there were no significant
group differences on habituation to the open field (F(4,208)= 0.840, p= 0.491; figure 11).
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Figure 10. Distance traveled during the thirty-minute open field locomotor assessment. Values
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Figure 11. Distance traveled during the thirty-minute open field locomotor assessment separated
into five-minute bins. Values are means ± SEM.
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Anxiety-Like Behavior
Three days following the open field, rats chronically treated with MPH during
periadolescence were tested in an elevated plus maze. The MPH treated rats (n= 14) spent a
similar amount of time spent in the open arms of the elevated plus maze compared to vehicletreated rats (n= 15) during adulthood (duration: F(l, 25) =0.083, p= 0.776; proportion: F(l, 25)
=0.064, p= 0.802). Rats chronically treated with MPH during periadolescence also had a similar
number of open and total arm entries compared to vehicle-treated rats, (open: F(l, 25) =0.221, p=
0.642; total: F(l, 25) =0.033, p= 0.858). Thus, early treatment with MPH had no long-term
effects on measures in the elevated plus maze. Although 19% of rats overall fell from/jumped
off the maze during the 5 minute test, drug condition did not affect the likelihood of a rat falling
off of the EPM (χ(1) = 0.166, p = .684). Rats were excluded from analysis if they fell on their
first time out onto an open arm without first having entered a closed arm, resulting in 3 excluded
rats.
Rats that were restrained for one hour prior to elevated plus maze testing (n= 14) spent a
similar amount of time in the open arms compared to rats that were not restrained (n= 15;
duration: F(l, 25) =0.357, p= 0.556; proportion: F(l, 25) =0.997, p= 0.328). Restrained rats also
did not have more open arms entries than non-restrained rats, (F(l, 25) =0.706, p= 0.409) or total
entries (F(l, 25) =2.243, p= 0.147). Restrained animals were less likely to fall off of the EPM
than non-restrained rats (χ(1) = 5.639, p = 0.018). There were no significant interactions between
drug treatment and restraint condition for proportion of time in open arms (F(l, 25) =0.874, p=
0.359), open arm entries (F(l, 25) =1.903, p= 0.180), or total arm entries (F(l, 25) =0.922, p=
0.346). A high degree of reliability was found between the two ratings. The average intraclass
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correlation coefficient was .983 with a 95% confidence interval from .962 to .992 (F(27,27)
=55.578, p< 0.001). Table 1 provides a summary of the observations for the elevated plus maze.

Table 1. Mean ± SEM for open arm entries, total arm entries, and proportion of time spent in
open arms during the five-minute elevated plus maze assessment.
Number of Open
Arm Entries

Total Number of
Arm Entries

Proportion of Time
Spent in Open Arms

Vehicle- No Stress

5.625 ± 0.944

11.125 ± 1.716

0.577 ± 0.095

Vehicle- Restraint

5.000 ± 1.291

12.000 ± 1.195

0.389 ± 0.092

MPH- No Stress

4.429 ± 1.131

9.857 ± 1.945

0.511 ± 0.113

MPH- Restraint

7.143 ± 1.353

13.857 ± 1.503

0.504 ± 0.085

FOS Immunoreactivity
Representative figures of the PFC and PVN are presented in figures 12 and 13,
respectively. There was no difference overall in FOS immunoreactivity between rats treated
during periadolescence with MPH (n= 10) compared to vehicle treated controls (n= 12) in the
PFC (F(l, 18) =0.570, p= 0.460) or PVN (F(l, 18) =1.156, p= 0.296; figures 14 and 15).
However, acute restraint stressed rats (n= 10) had increased FOS in both the PFC (F(l, 18)
=18.306, p< 0.01) and PVN (F(l, 18) =31.450, p<0.01) as compared to non-restrained rats (n=
12). Post hoc analyses revealed that stress increased FOS in both regions for both vehicle treated
and MPH treated rats. There was no interaction between periadolescence treatment and restraint
stress in FOS in either the PFC (F(l, 18) = 1.501, p= 0.236) or the PVN (F(l, 18) =0.243, p=
0.628). A high degree of reliability was found between double counts of the PFC. The average

45
intraclass correlation coefficient was .989 with a 95% confidence interval from .979 to .995
(F(21,63) =90.488, p< 0.001). A high degree of reliability was also found between double
counts of the PVN. The average intraclass correlation coefficient was .874 with a 95%
confidence interval from .758 to .942 (F(21,63) =7.744, p< 0.001).

A

Figure 12. Representative pictures of the sections used for FOS analysis in the PFC. Inset
images are magnified to show FOS positive cells. A) Vehicle-treated, unrestrained. B) Vehicletreated, restrained. C) MPH-treated, unrestrained. D) MPH-treated, restrained. Scale bar = 200
μm.
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Figure 13. Representative pictures of the sections used for FOS analysis in the PVN. Inset
images are magnified to show FOS positive cells. A) Vehicle-treated, unrestrained. B) Vehicletreated, restrained. C) MPH-treated, unrestrained. D) MPH-treated, restrained. Scale bar = 200
μm.
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Figure 14. FOS activation in the infralimbic prefrontal cortex as compared to vehicle-no stress
group; * denotes p <.05 of restrained stress rats compared to non-restrained rats in post hoc
analyses. Values are means ± SEM.

Percent of Vehicle-No Stress Group

500

*

400

*

300

200

100

0
Vehicle- No Stress

Vehicle- Stress

MPH- No Stress

MPH- Stress

Figure 15. FOS activation in the paraventricular hypothalamic nucleus as compared to vehicle-no
stress group; * denotes p <.05 of restrained stress rats compared to non-restrained rats in post hoc
analyses. Values are means ± SEM.

DISCUSSION
The current experiment examined the long-term effects of chronic juvenile
methylphenidate treatment in male rats on the FOS and behavioral responses to an acute stressor
in adulthood. This is the first experiment to investigate the effects of repeated juvenile MPH
treatment on stress systems and stress-related behaviors during adulthood in rats. We
hypothesized that juvenile treatment with MPH would not alter basal FOS immunoreactivity in
two brain regions strongly associated with stress responses, the PVN and PFC, but would
attenuate FOS immunoreactivity when the stress systems were activated by restraint stress
(Hypotheses 1A and 1B). While basal FOS immunoreactivity was not affected by MPH as
hypothesized, MPH treated rats showed similar stress-induced increases in FOS compared to
control rats. In addition, we hypothesized that juvenile treatment with MPH would have an
anxiolytic effect in the elevated plus maze, but no effect on general locomotion when measured
in adulthood (Hypotheses 2A and 2B). The data showed no long-term effects of juvenile
methylphenidate treatment on either locomotion or anxiety-like behaviors in the elevated plus
maze in adulthood. Collectively, these data suggest that early exposure to MPH does not alter
FOS expression or stress-related behaviors; the potential reasons and implications for these
findings will be discussed.
For this study, the behavioral testing and immediate early gene immunoreactivity was
measured approximately 63 days after the last exposure to MPH. Thus, all rats’ behaviors and
FOS measures were assessed drug-free and after a protracted withdrawal period. Relatively few
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papers have investigated the long-term effects of MPH or other stimulants in humans or animals
with a long-term withdrawal from the drug (McFadyen, Brown, Carrey, 2002; Gray et al., 2007;
Konrad, Neufang, Fink, & Herpertz-Dahlmann, 2007). One study assessed anxiety-like
behaviors 100 days after treatment using a higher dose of MPH (5 mg/kg) administered twice
daily from PD 7-35. Rats treated with MPH showed decreased anxiety on PD 135 as adults
compared to control rats (Gray et al., 2007). Another study administered 2.0 mg/kg i.p. MPH
twice daily from PD 20-35 and also found decreased time in the open arms of the EPM when
assessed rats six weeks after the drug exposure (Bolanos, Barrot, Berton, Wallace-Black, and
Nestler, 2003). In a human imaging study, Konrad, Neufang, Fink, & Herpertz-Dahlmann
(2007) reported that insular and striatal brain regions had reduced activation during a reorienting
task after one year of MPH treatment as compared to a compensatory increase in activity prior to
treatment, suggesting that MPH may have normalizing effects in ADHD diagnosed individuals
within regions involved in attention. Together, these data suggest MPH may have differential
effects on constructs like attention, memory, and anxiety. There are no comparable data on the
long-term effects of stimulants on stress systems, but the potential interaction warranted an
investigation.
Both vehicle and MPH treated rats showed an increase in FOS following an acute
restraint stressor, as seen in previous research (Cullinan et al., 1995). This increase in FOS was
prominent in the infralimbic prefrontal cortex and paraventricular hypothalamic nucleus, two
brain regions that are known to be involved in a typical stress response (see figures 12 and 13;
Cullinan et al., 1995; Pascucci et al., 2007). The one-hour acute restraint stressor was sufficient
to induce FOS activation significantly above basal levels 45 minutes after the end of stress,
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suggesting that restraint stress is sufficient to increase the expression of FOS. Our findings
complement previous literature that found increases in FOS immediately, 30 minutes, or 2 hours
following 30 minutes to 4 hours of restraint (Chowdhury, Fujioka, & Nakamura, 2000; Zavala,
Fernandez, & Gosselink; Cullinan et al., 1995). While both groups of rats showed the stressinduced increase in FOS, rats treated with MPH had similar levels to vehicle treated rats,
suggesting that FOS expression in response to stress was not affected by early stimulant
treatment.
FOS immunoreactivity was chosen as our marker of cellular activation because it is
rapidly and transiently expressed in response to neurotransmitters released in the brain by a
variety of stimuli (Hoffman, Smith, & Verbalis, 1993), including stress (Cullinan et al, 1995;
Chowdhury, Fujioka, & Nakamura, 2000). While FOS is a commonly used marker of cellular
activation, it is not exclusively found in neurons. FOS is also expressed in glial cells (Bennett &
Schwartz, 1994), but no known experiments have examined an increase in expression of glial
FOS in response to stress, whereas research has investigated stress-induced FOS expression with
glucocorticoid receptors or corticotropic releasing factor mRNA in neurons (Zavala, Fernandez,
& Gosselink, 2011; Babb, Masini, Day, & Campeau, 2013). Co-labeling FOS with another
neuronal marker, such as the general neuronal marker Neu-N or the specific marker tyrosine
hydroxylase, may provide a more nuanced understanding of the lasting effects of MPH exposure
during periadolescence. For the current study, it is possible that FOS immunoreactivity was
selectively attenuated by prior MPH treatment in a specific cell type such as tyrosine
hydroxylase neurons, but that generalized counting of FOS revealed no overall treatment effect.
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Investigating potential long-term effects of MPH on specific cell types may be critical to provide
a better understanding of the circuitry targeted by MPH administration and its function.
Psychostimulants are most commonly administered orally in humans and therefore, the
oral administration of MPH in the current study increased the clinical validity of the project
(Ferguson & Boctor, 2009). To avoid the potential stress associated with oral gavage in animals
(Brown, Dinger, & Levine, 2000), the unforced method of drug administration via a vanilla
wafer cookie was utilized. Although oral administration is clinically important, our hypotheses
were predicated on previous literature that administered MPH via intraperitoneal injections. It is
well established that pharmacokinetic properties of MPH differ based on route of administration
(Kuczenski & Segal, 2005; Volkow, Fowler, Wang, Ding, & Gatley, 2002). For example,
intraperitoneal injections in rats yield greater blood plasma concentrations of MPH than the
targeted range for human therapeutic dosing and the plasma concentrations increased more
quickly than oral administration (Kuczenski & Segal, 2005). In addition, intraperitoneal
injections result in greater DA release in the nucleus accumbens (Gerasimov et al., 2000), and
can have different effects on locomotion/behavior than oral administration (Gerasimov et al.,
2000; Kuczenski & Segal, 2005). Using an increased dose of MPH or a different route of
administration may have potentially yielded results more consistent with prior studies, albeit
perhaps less clinically relevant. Increasing dose or using a faster-acting route of administration
increases the potency of the drug, which may increase the potential for long-term circuitry
alterations.
Again, the dose and route of administration of MPH may be important for the behavioral
effects; this is one potential reason juvenile MPH treatment did not influence anxiety-like
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behavior on the EPM. Bolanos, Barrot, Berton, Wallace-Black, and Nestler (2003) administered
2.0 mg/kg MPH via intraperitoneal injection twice daily from PD 20 to PD 35 and MPH treated
rats showed increased anxiety-like behavior when tested 6 weeks following the last drug
administration. Therefore, the single daily oral dose of 2.0 mg/kg given in this study was lower
than their dosing and at the lower end of the range of doses typically used in MPH research
(Harvey, Sen, Deaciuc, Dwoskin, & Kantak, 2011; Kuczenski & Segal, 1997; Volkow et al.,
2001; Volkow, Fowler, Wang, Ding, & Gatley, 2002). It is quite possible that a higher dose
would have resulted in long-term behavioral effects. Previous research that has shown that
chronic 2.0 to 40.0 mg/kg MPH decreased anxiety used intraperitoneal or subcutaneous
injections (Gray et al., 2007, Carrey, McFadyen, & Brown, 2000; Crawford et al., 2013).
The injection procedure alone has been shown to increase physiological stress, such as
heart rate (Meijer, Spruijt, van Zutphen, & Baumans, 2006), corticosterone (Drude et al., 2011;
after repeated administration, suggesting sensitization and not habituation), and FOS expression
in the PVN 1, 3, and 6 hours post injection (Ceccatelli, Villar, Goldstein, & Hokfelt, 1989).
Thus, the long-term effects of MPH on anxiety observed in previous papers may be due to the
combination of the stress associated with injection and MPH rather than the drug alone.
Previous literature has shown that chronic 10.0 mg/kg MPH (PD22-46) and parental separation
stress for three weeks cross-sensitizes dopamine systems in the medial prefrontal cortex and
nucleus accumbens (Jezierski, Zehle, Bock, Braun, & Gruss, 2007). By eliminating the stress of
oral gavage or injection administration, we could have reduced the procedural stress, attenuating
the long-term effects of stress or stress by MPH interaction on anxiety-like behavior.
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Although FOS was increased in the PFC and PVN following acute restraint stress, there
were no behavioral changes observed as measured in the EPM. While the EPM is a wellaccepted and widely used measure of anxiety-like behavior in rodents (Walf & Frye, 2007), there
are some limitations to the assessment that should be considered. Traditionally, anxiety-like
behavior is measured through the time spent in the closed arm compared to the open arm
(Pellow, Chopin, File, & Briley, 1985). However, rodents spend a large amount of time in the
central area of the maze and this is challenging to interpret. Some researchers argue that an
animal stopped in the central region is undergoing a decision-making strategy (Rodgers &
Johnson, 1995) or risk assessment (as assessed by stretched attend posture; Grewal, Shephard,
Bill, Fletcher, & Dourish, 1997), which may be distinct from anxiety-related processes. To
reduce the concern with the central region for the current study, time in the open or closed arms
was operationally defined as all 4 paws in the appropriate arm, none in the central region. Even
with this approach to assessing behavior, the amount of time spent in the open arms by vehicle or
MPH treated rats did not differ. Future research may benefit from exploring other measures of
anxiety-like behavior, such as light/dark exploration tasks or the zero maze, which has no middle
region (Shepherd, Grewal, Fletcher, Bill, & Dourish, 1994).
In the current experiment, standard laboratory Sprague Dawley rats were used rather than
rats or mice bred as an animal model of ADHD. An animal model of ADHD, such as the
Spontaneously Hypertensive rat (SHR) strain, may be more appropriate and clinically valid. The
SHR strain is a rat model for ADHD due to its hyperactivity and was bred from Wistar Kyoto
rats with high blood pressure (McCarty & Kopin, 1979). MPH appears to have different effects
on different strains (Somkuwar, Darna, Kantak, & Dwoskin, 2013; Harvey, Sen, Deaciuc,

54
Dwoskin, & Kantak, 2011). Yang, Amini, Swann, & Dafny (2003) found that chronic 2.5 mg/kg
i.p. MPH produced locomotor sensitization in adult Sprague Dawley rats, but not in SHR rats.
Interestingly, Sprague Dawley rats have been shown to have increased anxiety-like behavior as
compared to the SHR strain and the Wistar Kyoto strain (Ferguson & Cada, 2004). Thus, the
effects of MPH and basal anxiety-levels appear to vary based on the animal’s genotype,
indicating that our hypotheses may be supported by data in other strains. Potentially, with our
rats exhibiting no preference for closed arms over open arms, the data could be approaching a
ceiling effect of anxiogenic behavior, which may help explain the lack of a treatment or stress
effect. The current research may be important for the growing body of clinical data that suggests
human stimulant use in normal individuals, with a typical genotype, is on the rise.
Methylphenidate is termed a ‘smart drug’ or ‘cognitive enhancer’ that is taken by non-diagnosed
individuals to improve learning and attention processes (for review, see Smith & Farah, 2011). It
is important to consider the long-term effects of drugs not only in the individuals with the ADHD
pathology, but also in normal individuals who may recreationally use the drug for cognitive
enhancement purposes.
The current project investigated the long-term effects of MPH on males, as males are
more commonly diagnosed and prescribed psychostimulant treatment than females (CDC, 2011).
The differential rates of diagnosis suggest a possible sex difference in children’s brain
development that renders boys more susceptible to ADHD symptomology than girls. Female
humans overproduce receptors and synapses earlier than males (Geidd et al., 1999), but generally
overproduce to a lesser extent (Andersen, 2003). It is thought that sex-related differences in
maturation contribute to age-related changes in sex differences. ADHD diagnosed individuals
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tend to have smaller caudate volumes than normal controls, but these differences subside
throughout maturation/adolescence, which may alleviate symptoms of hyperactivity and
impulsivity (Castellanos et al., 2002). Gray matter volumes of the caudate nucleus peak earlier
for females than for males (around 10.5 and 14 years old, respectively; Lenroot et al., 2007),
which also may help explain why ADHD diagnosis is more prevalent in males. Due to
differences in development and diagnosis, it is not surprising that there might also be a sex
difference regarding the effects of methylphenidate treatment. In fact, a sex difference in
methylphenidate exposure has been observed in humans (Sonuga-Barke et al., 2007) and rodents
(Bentley, Snyder, Brown, Brown, & Pond, 2015). Female rats had higher brain concentration of
MPH and slower clearance at multiple time points after a 5.0 mg/kg dose as compared to males
(Bentley et al., 2015). Future research should investigate the long-term effects of chronic
juvenile MPH treatment on a later adulthood stress response in females as their neural
developmental patterns differ slightly from males, as well as their sensitivity to stimulants.
In addition to sex differences observed with prevalence rates in ADHD, females also
appear to be more sensitive to the effects of stress and are more vulnerable than males to
developing stress-related psychiatric illnesses, such as depression and generalized anxiety
disorder (McLean, Asnaani, Litz, & Hofmann, 2011). Female rats have shown greater neural
sensitivity to stress with higher FOS expression than males in the PVN, anteroventral division of
the bed nucleus of the stria terminalis, and the medial preoptic area following thirty minutes of
restraint stress (Babb, Masini, Day, & Campeau, 2013). Generally, females have quicker
activation of the HPA axis and higher release of stress hormones (for review, see Goel,
Workman, Lee, Innala, & Viau, 2014). Previous research has suggested a role for gonadal
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hormones in females’ heightened behavioral responses to stress. Female rats in proestrus spend
more time in the open arms of the elevated plus maze than those in diestrus, indicating that
estradiol levels may mediate anxiety-like behavior (Marcondes, Miguel, Melo, & SpadariBratfisch, 2001). Although there was no effect of MPH on the stress response in male rats,
females’ vulnerability to stress coupled with the increased sensitivity to stimulants (ChatterjeeChakrabarty, Miller, Collins, & Nagamani, 2005) may yield different results.
One interesting avenue of future research would be to investigate the role of stress
hormones in mediating long-term responses to MPH during periadolescence. Previous literature
has shown that other stimulants, like methamphetamine, increase corticosterone 1 to 72 hours
post-injection (Herring et al., 2008), which suggests that stress hormones themselves could be
responsible for the long-term changes occurring within the circuitry due to exposure to
stimulants. Stress hormones could be increasing daily with the exposure to MPH, which in turn
alter other stress neural circuits not captured by the current study. FOS is a very broad measure
of cellular activation and it is unknown exactly how restraint stress is inducing its expression.
FOS could be activated by CRF, glucocorticoids, neurotransmitters like dopamine or
norepinephrine, or other factors stimulated during a stressful experience. While we hypothesized
long-lasting effects of periadolescent methylphenidate treatment, the mechanism underlying such
an effect is unknown. Although the current data did not demonstrate any long-lasting effects,
this could be due to a disconnect between what part of the circuitry is actually being altered by
periadolescent exposure to MPH versus the downstream effects we were measuring via FOS.
Investigating stress hormones and other mechanisms of action may help understand whether
MPH mediates stress.
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Because of its function, the prefrontal cortex was and is still currently studied as the
predominant brain region implicated in ADHD. In the future, FOS could be analyzed in other
brain regions being investigated, including the caudate, locus coeruleus, and amygdala. Many
brain regions are significantly reduced in children with ADHD compared to controls that could
be investigated, including the caudate (Castellanos et al., 2002). Anatomical differences in the
caudates of children with ADHD help explain symptoms of hyperactivity and are normalized
with MPH treatment (Castellanos et al., 2002). The locus coeruleus contains noradrenergic
neurons that project throughout the brain; projections to the PFC are critical for attention and
arousal (for review, see Sara & Bouret, 2012). Stimulants work to normalize noradrenergic cell
communication; this normalization alleviates inattention symptoms seen in ADHD patients
(Arnsten, 2009). There is evidence for the role of noradrenergic symptoms seen by symptom
correction with methylphenidate and symptom induction (hyperactivity) with yohimbine (Ma,
Arnsten, & Li, 2005). Further, norepinephrine is released following stress primarily from the LC
(Tsigos & Chrousos, 2002), which is influenced by CRF and the HPA axis (Jedema & Grace,
2004), thus making this a potential region of interest for the MPH by stress interaction.
In summary, periadolescent exposure to methylphenidate had no effect on FOS
expression or the behavioral stress response in adulthood; it neither augmented nor attenuated the
effects of restraint stress. Clinically, finding no long-term effect of methylphenidate may be
considered a positive outcome for the 6.1% of children in the U.S. currently taking
psychostimulant treatment for ADHD (CDC, 2011). There is very little literature on the longterm effects of early exposure to stimulant medications, but this research is highly important to
understand because of the potential vulnerability of the individuals who are prescribed these
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medications: young children. While MPH may have beneficial long-lasting effects on constructs
such as neurocognitive function (Huang, Wang, & Chen, 2012; Tsai et al., 2013), there is
concern for potential long-lasting negative effects in other domains such as drug abuse/addiction
(Robinson & Berridge, 1993; Calipari & Jones, 2014). The current project purports that MPH
has no long-lasting effect on stress-related circuitry or anxiety-like behavior and this lack of
effect may help alleviate public concern about providing pharmacotherapies for ADHD, such as
MPH (Bussing et al., 2012).
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